Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

All news

Show

From To
Dapivirine vaginal ring safe, acceptable for HIV prevention in teens

A monthly vaginal ring containing the antiretroviral dapivirine has demonstrated efficacy in girls younger than 18 years, according to phase 2a study results presented at the IAS Conference on HIV Science.

Published
1 hour ago
From
Healio
IAS 2017: UNITAID, partners boost HIV self-test access in six African countries

The UNITAID-led HIV Self-Testing Africa consortium will expand the reach of its project from Malawi, Zambia and Zimbabswe to include South Africa Lesotho and Swaziland leaders of the effort announced here Monday.

Published
1 hour ago
From
Science Speaks
Vertical HIV transmission may be influenced by complex synergies with other STI – such as Cytomegalovirus

The apparently greater susceptibility of sub-Saharan African women to HIV infection has led researchers to consider the various potential synergies between HIV and other genital infections or conditions of the vaginal microbiome. A recent study brings this wider perspective to bear on mother-to-child transmission, casting some fresh light on the complex interrelation between the ‘vertical’ transmission of HIV and active and Cytomegalovirus (CMV) viruria.

Published
2 hours ago
From
BMJ Group blogs
ECDC estimate: Around 9 million Europeans are affected by chronic hepatitis B or C

An estimated 4.7 million Europeans are living with chronic hepatitis B and almost 4 million with chronic hepatitis C infection. But large numbers of them are not aware of their infection as they have not yet been diagnosed. On of World Hepatitis Day, ECDC Director Andrea Ammon highlights the need for Europe to scale-up coverage of testing, prevention interventions and linkage to suitable treatment services to achieve the target of eliminating viral hepatitis by 2030.

Published
2 hours ago
From
Eurekalert Inf Dis
Rectal products for PrEP: Are they an option?

At the IAS 2017 conference this week, Ian McGowan, MD, PhD, FRCP, from University of Pittsburgh, discussed the need for (and challenges associated with) topical HIV prevention products, and a separate team of researchers presented promising findings from a very early study of a rectal HIV-prevention douche.

Published
2 hours ago
From
BETA blog
What can science learn from a child who has controlled HIV without drugs for more than 8 years?

An HIV-infected child in South Africa who is controlling the virus without antiretroviral (ARV) drugs has reinvigorated the push to find ways to allow people to control the virus for prolonged periods without treatment.

Published
2 hours ago
From
Science
Long-acting cabotegravir injection shows promise for HIV prevention

A long-acting injectable formulation of cabotegravir given every 8 weeks produces high enough drugs levels in both men and women to offer protection against HIV, according to

Published
3 hours ago
By
Liz Highleyman
Doravirine combination pill looks good for initial HIV treatment

A single-tablet regimen containing the next-generation NNRTI doravirine reduced HIV viral load as much as an efavirenz-based coformulation, but it had a more favourable side-effect profile, according

Published
3 hours ago
By
Liz Highleyman
Acute kidney injury ‘uncommon’ but unpredictable on tenofovir and ritonavir

Doctors need to monitor patients regularly for kidney function if they are taking tenofovir disoproxil, especially if combined with ritonavir, the 9th International AIDS Society Conference on HIV

Published
5 hours ago
By
Gus Cairns
Countries and donors should aim for new $90-$90-$90 target on HIV, hepatitis, TB drug prices, study shows

HIV, hepatitis B and C and tuberculosis (TB) can each be treated for less than $90 a year where generic drugs can be made available, Dzintars Gotham

Published
5 hours ago
By
Keith Alcorn
← First12345...2294Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.